Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4: Adagrasib plus pembrolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in KRAS G12C-mutated non-squamous NSCLC
jRCT2041250172Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Adagrasib + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival (PFS) by blinded independent central review (BICR) and Overall survival (OS). Started Jan 2026; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041250172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250172.